BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kelley RK, Meyer T, Rimassa L, Merle P, Park JW, Yau T, Chan SL, Blanc JF, Tam VC, Tran A, Dadduzio V, Markby DW, Kaldate R, Cheng AL, El-Khoueiry AB, Abou-Alfa GK. Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma. Clin Cancer Res 2020;26:4795-804. [PMID: 32636319 DOI: 10.1158/1078-0432.CCR-19-3884] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Decaens T, Barone C, Assenat E, Wermke M, Fasolo A, Merle P, Blanc JF, Grando V, Iacobellis A, Villa E, Trojan J, Straub J, Bruns R, Berghoff K, Scheele J, Raymond E, Faivre S. Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression. Br J Cancer 2021;125:190-9. [PMID: 33824476 DOI: 10.1038/s41416-021-01334-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Kang SM, Khalil L, El-Rayes BF, Akce M. Rapidly Evolving Landscape and Future Horizons in Hepatocellular Carcinoma in the Era of Immuno-Oncology. Front Oncol 2022;12:821903. [PMID: 35433430 DOI: 10.3389/fonc.2022.821903] [Reference Citation Analysis]
3 Kim BH, Park J. Systemic therapy for advanced hepatocellular carcinoma: consideration for selecting second-line treatment. J Liver Cancer 2021;21:124-38. [DOI: 10.17998/jlc.2021.09.23] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Finkelmeier F, Scheiner B, Leyh C, Best J, Fründt TW, Czauderna C, Beutel A, Bettinger D, Weiß J, Meischl T, Kütting F, Waldschmidt DT, Radu P, Schultheiß M, Peiffer KH, Ettrich TJ, Weinmann A, Wege H, Venerito M, Dufour JF, Lange CM, Pinter M, Waidmann O. Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort. Liver Cancer 2021;10:360-9. [PMID: 34414123 DOI: 10.1159/000515490] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Lyu N, Wang X, Li JB, Lai JF, Chen QF, Li SL, Deng HJ, He M, Mu LW, Zhao M. Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1). J Clin Oncol 2021;:JCO2101963. [PMID: 34905388 DOI: 10.1200/JCO.21.01963] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
6 Trojan J, Mollon P, Daniele B, Marteau F, Martín L, Li Y, Xu Q, Piscaglia F, Zaucha R, Sarker D, Lim HY, Venerito M. Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison. Adv Ther 2021;38:2472-90. [PMID: 33822328 DOI: 10.1007/s12325-021-01700-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Bang YH, Lee C, Yoo C, Chon HJ, Hong M, Kang B, Kim H, Park SR, Choi W, Choi J, Lee D, Shim JH, Kim KM, Lim Y, Lee HC, Ryu M, Ryoo B. Real-world efficacy and safety of cabozantinib in Korean patients with advanced hepatocellular carcinoma: a multicenter retrospective analysis. Ther Adv Med Oncol 2022;14:175883592210979. [DOI: 10.1177/17588359221097934] [Reference Citation Analysis]
8 D'Alessio A, Prete MG, Cammarota A, Personeni N, Rimassa L. The Role of Cabozantinib as a Therapeutic Option for Hepatocellular Carcinoma: Current Landscape and Future Challenges. J Hepatocell Carcinoma 2021;8:177-91. [PMID: 33824862 DOI: 10.2147/JHC.S268310] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Li XY, Wang DP, Li S, Xue WH, Qian XH, Liu KL, Li YH, Lin QQ, Dong G, Meng FH, Jian LY. Discovery of N-(1,3,4-thiadiazol-2-yl)benzamide derivatives containing a 6,7-methoxyquinoline structure as novel EGFR/HER-2 dual-target inhibitors against cancer growth and angiogenesis. Bioorg Chem 2021;119:105469. [PMID: 34915285 DOI: 10.1016/j.bioorg.2021.105469] [Reference Citation Analysis]
10 Zaidi S, Amdur R, Xiang X, Yu H, Wong LL, Rao S, He AR, Amin K, Zaheer D, Narayan RK, Satapathy SK, Latham PS, Shetty K, Guha C, Gough NR, Mishra L. Using quantitative immunohistochemistry in patients at high risk for hepatocellular cancer. Genes Cancer 2022;13:9-20. [PMID: 35677836 DOI: 10.18632/genesandcancer.220] [Reference Citation Analysis]
11 Zhu C, Xiao H, Jiang X, Tong R, Guan J. Prognostic Biomarker DDOST and Its Correlation With Immune Infiltrates in Hepatocellular Carcinoma. Front Genet 2022;12:819520. [DOI: 10.3389/fgene.2021.819520] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
12 Cammarota A, Zanuso V, D'Alessio A, Pressiani T, Bozzarelli S, Personeni N, Rimassa L. The dual checkpoint blockade in unresectable hepatocellular carcinoma: Opportunities emerging in clinical trials. Expert Opin Investig Drugs 2022. [PMID: 35152830 DOI: 10.1080/13543784.2022.2042253] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]